

NEWSLETTER

CHEMICAL & PHARMACEUTICAL

12 - 18 January 2026



China announced the initiation of an anti-dumping investigation into imported dichlorosilane

In accordance with Article 16 of the Anti-dumping Regulations of the People's Republic of China, the Ministry of Commerce has decided to initiate an anti-dumping investigation into imports of dichlorosilane originating in Japan, effective January 7, 2026. The dumping investigation period is from July 1, 2024 to June 30, 2025, and the injury investigation period is from January 1, 2022 to June 30, 2025. **(Ministry of Commerce)**

A New Wave of Lithium Iron Phosphate Capacity Expansion Begins

After two or three years of industry adjustment, the lithium iron phosphate (LFP) industry is signaling a new wave of capacity expansion. In 2024, the industry's capacity utilization rate was only about 50%. However, with the explosive growth of the energy storage market and the continuous increase in the penetration rate of new energy vehicles since 2025, industry demand has rebounded rapidly. **(ChemNet Chemical Industry Headlines)**

Fulim Precision decided to build 500,000-ton capacity and supporting precursors

On January 5, 2026, Fulim Precision disclosed a major investment plan. Its wholly-owned subsidiary, Jiangxi Shenghua New Materials Co., Ltd., plans to sign a cooperation agreement with the People's Government of Yijinhuluo Banner, Ordos City, to invest in the construction of a 500,000-ton-per-year high-end energy storage lithium iron phosphate project, with a total investment of 6 billion yuan (€0.73 billion). **(ChemNet Chemical Industry Headlines)**

Opella to deepen presence in China

French healthcare company Opella is strengthening its commitment to China, recognizing it as a core market and a key growth engine. The company plans to expand access to self-care through local innovation and by leveraging China's advanced e-commerce infrastructure. This strategy aligns with China's shift toward preventive healthcare and its rapidly growing OTC (Over-The-Counter) market, driven by an aging population. **(China Daily)**

Astellas plans further expansion in China

Japanese pharmaceutical firm Astellas is accelerating its expansion in China, its fourth-largest market, after achieving record growth. The company's China revenue surged 57.8% in a recent quarter, driven by innovative therapies like a first-in-class gastric cancer treatment. Astellas has integrated China into its global drug development as a first-tier region, enabling simultaneous launches. **(China Daily)**